Physician profile
Patrick S Baquet
NPI 1326078577
$5,492.25
in general payments reported to CMS, 2019-2025
51 companies · $835 in 2025
The $835 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $421 · 2021: $714 · 2022: $733 · 2023: $824 · 2024: $1,181 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,839.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,330.95 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $472.30 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Corium, LLC | $446.11 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $368.58 | 2019-2025 | Trintellix |
| Allergan, INC. | $245.98 | 2019-2020 | |
| Lilly USA, LLC | $242.68 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $225.55 | 2019-2025 | |
| Amgen INC. | $209.58 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $170.34 | 2019-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $122.36 | 2024-2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $114.30 | 2021-2023 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.90 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $94.88 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $87.82 | 2019-2023 | Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.65 | 2022-2025 | Caplyta |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Baquet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.